Anan S. Raghunath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anan S. Raghunath has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amritpal P. S. Hungin
Emeritus Professor of General Practice, Faculty of Medical Sciences Newcastle University Newcastle upon Tyne UK
4 shared publications - James Mason
Warwick Medical School, University of Warwick, Coventry, UK
2 shared publications W. Jackson
Gastro‐Intestinal Physiology Laboratory, Castle Hill Hospital, East Yorkshire, UK
2 shared publicationsA. Innes
1 shared publicationA. P. S. Hungin
School of Medicine and Health, Durham University, Wolfson Research Institute, University Boulevard, Stockton‐on‐Tees, UK
1 shared publicationAlyn H. Morice
1 shared publication
Latest Publications
- Open Access
- 8 January 2009
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (4) , 431-439
Symptoms in patients on long‐term proton pump inhibitors: prevalence and predictors
Summary: Background Symptom control in primary care patients on long‐term proton pump inhibitor (PPI) treatment is poorly understood.Aim To explore associations between symptom control and demographics, lifestyle, PPI use, diagnosis and Helicobacter pylori status.Methods A cross‐sectional survey (n = 726) using note reviews, questionnaires and carbon‐13 urea breath testing. Determinants of symptom control [Leeds Dyspepsia Questionnaire (LDQ), Carlsson and Dent Reflux Questionnaire (CDRQ), health‐related quality‐of‐life measures (EuroQoL: EQ‐5D and EQ‐VAS)] were explored using stepwise linear regression.Results Moderate or severe dyspepsia symptoms occurred in 61% of subjects (LDQ) and reflux symptoms in 59% (CDRQ). Age, gender, smoking and body mass index had little or no influence upon symptom control or PPI use. Average symptom scores and PPI use were lower in patients with non‐ulcer dyspepsia and gastro‐protection than gastro‐oesophageal reflux disease (GERD) and uninvestigated dyspepsia. H. pylori infection was associated with lower reflux symptom scores only in patients with GERD and uninvestigated dyspepsia. EQ‐5D was not able to discriminate between diagnostic groups, although the EQ‐VAS performed well.Conclusions A majority of patients suffered ongoing moderate or severe symptoms. GERD and uninvestigated dyspepsia were associated with poorer long‐term symptom control; H. pylori appeared to have a protective effect on reflux symptoms in these patients.
- 8 January 2009
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (4) , 431-439
Open AccessSymptoms in patients on long‐term proton pump inhibitors: prevalence and predictors
Summary: Background Symptom control in primary care patients on long‐term proton pump inhibitor (PPI) treatment is poorly understood.Aim To explore associations between symptom control and demographics, lifestyle, PPI use, diagnosis and Helicobacter pylori status.Methods A cross‐sectional survey (n = 726) using note reviews, questionnaires and carbon‐13 urea breath testing. Determinants of symptom control [Leeds Dyspepsia Questionnaire (LDQ), Carlsson and Dent Reflux Questionnaire (CDRQ), health‐related quality‐of‐life measures (EuroQoL: EQ‐5D and EQ‐VAS)] were explored using stepwise linear regression.Results Moderate or severe dyspepsia symptoms occurred in 61% of subjects (LDQ) and reflux symptoms in 59% (CDRQ). Age, gender, smoking and body mass index had little or no influence upon symptom control or PPI use. Average symptom scores and PPI use were lower in patients with non‐ulcer dyspepsia and gastro‐protection than gastro‐oesophageal reflux disease (GERD) and uninvestigated dyspepsia. H. pylori infection was associated with lower reflux symptom scores only in patients with GERD and uninvestigated dyspepsia. EQ‐5D was not able to discriminate between diagnostic groups, although the EQ‐VAS performed well.Conclusions A majority of patients suffered ongoing moderate or severe symptoms. GERD and uninvestigated dyspepsia were associated with poorer long‐term symptom control; H. pylori appeared to have a protective effect on reflux symptoms in these patients.
- Open Access
- 21 December 2006
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (5) , 585-592
Helicobacter pylori eradication in long‐term proton pump inhibitor users in primary care: a randomized‐controlled trial
Summary: Background Two‐thirds of proton pump inhibitor prescribing in the UK is for long‐term therapy.Aim To determine the impact of eradication in long‐term proton pump inhibitor users infected with Helicobacter pylori.Methods A total of 184 H. pylori‐positive patients were randomly assigned to true or placebo eradication therapy. The primary outcome was the change in proton pump inhibitor usage measured by prescriptions; secondary outcomes were changes of proton pump inhibitor doses, dyspepsia symptoms, general practitioner consultations and quality of life measures.Results In the year following H. pylori eradication proton pump inhibitor prescriptions fell compared with placebo (−1.7, 95% CI: −2.3 to −1.1, P < 0.001); when adjusted to full‐dose equivalent prescriptions the reduction was more marked (−2.2, 95% CI: −3.0 to −1.4, P < 0.001). Both general practitioner consultations (−1.0, 95% CI: −1.8 to −0.1, P = 0.026) and symptoms measured on the Leeds Dyspepsia Questionnaire (−3.1, 95% CI: −5.3 to −0.9, P = 0.005) were reduced. Quality of life and self‐rating measures also favoured eradication (EQ‐5D: 0.09, P = 0.08 and VAS: 5.6, P = 0.002). The Carlsson and Dent Reflux Questionnaire found no difference between groups (−0.3, P = 0.65), possibly balancing decreased overall symptoms with increased prominence of heartburn in the eradication group.Conclusions Helicobacter pylori eradication in infected, long‐term proton pump inhibitor users in primary care reduced both the overall severity of symptoms and use of health care.
- 21 December 2006
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (5) , 585-592
Open AccessHelicobacter pylori eradication in long‐term proton pump inhibitor users in primary care: a randomized‐controlled trial
Summary: Background Two‐thirds of proton pump inhibitor prescribing in the UK is for long‐term therapy.Aim To determine the impact of eradication in long‐term proton pump inhibitor users infected with Helicobacter pylori.Methods A total of 184 H. pylori‐positive patients were randomly assigned to true or placebo eradication therapy. The primary outcome was the change in proton pump inhibitor usage measured by prescriptions; secondary outcomes were changes of proton pump inhibitor doses, dyspepsia symptoms, general practitioner consultations and quality of life measures.Results In the year following H. pylori eradication proton pump inhibitor prescriptions fell compared with placebo (−1.7, 95% CI: −2.3 to −1.1, P < 0.001); when adjusted to full‐dose equivalent prescriptions the reduction was more marked (−2.2, 95% CI: −3.0 to −1.4, P < 0.001). Both general practitioner consultations (−1.0, 95% CI: −1.8 to −0.1, P = 0.026) and symptoms measured on the Leeds Dyspepsia Questionnaire (−3.1, 95% CI: −5.3 to −0.9, P = 0.005) were reduced. Quality of life and self‐rating measures also favoured eradication (EQ‐5D: 0.09, P = 0.08 and VAS: 5.6, P = 0.002). The Carlsson and Dent Reflux Questionnaire found no difference between groups (−0.3, P = 0.65), possibly balancing decreased overall symptoms with increased prominence of heartburn in the eradication group.Conclusions Helicobacter pylori eradication in infected, long‐term proton pump inhibitor users in primary care reduced both the overall severity of symptoms and use of health care.
- 1 January 2006
- Published by Taylor & Francis in Journal of Asthma
- Vol. 43 (9) , 657-660
Difficulties in the Interpretation of Lung Function Tests in the Diagnosis of Asthma and Chronic Obstructive Pulmonary Disease
To ascertain differences in the interpretation of spirometry and peak flow measurement between primary care (several practioners and nurses) and specialists in patients with a pre-existing diagnosis of asthma and chronic obstructive pulmonary disease (COPD). A randomized, prospective cohort study of 98 patients with a pre-existing diagnosis of asthma or COPD. Two chest specialists independently interpreted the peak flow and spirometric data and they were also blinded to the primary care results. There was total agreement in interpretation of the data between general practitioners and specialists in only 20 (20.4%). Levels of diagnostic agreement were highest between the two chest specialists (55%) and lowest between the general practice records and the diagnosis assigned by general practitioners (16%). Disagreement between general practitioners and the two chest specialists was consistent (38%) indicating systematic differences in interpretation. This study raises concerns about differences in the interpretation of spirometry and peak expiratory flow rates in general and hospital practice and the guidelines on which these interpretations are based.
- 1 January 2006
- Published by Taylor & Francis in Journal of Asthma
- Vol. 43 (9) , 657-660
Difficulties in the Interpretation of Lung Function Tests in the Diagnosis of Asthma and Chronic Obstructive Pulmonary Disease
To ascertain differences in the interpretation of spirometry and peak flow measurement between primary care (several practioners and nurses) and specialists in patients with a pre-existing diagnosis of asthma and chronic obstructive pulmonary disease (COPD). A randomized, prospective cohort study of 98 patients with a pre-existing diagnosis of asthma or COPD. Two chest specialists independently interpreted the peak flow and spirometric data and they were also blinded to the primary care results. There was total agreement in interpretation of the data between general practitioners and specialists in only 20 (20.4%). Levels of diagnostic agreement were highest between the two chest specialists (55%) and lowest between the general practice records and the diagnosis assigned by general practitioners (16%). Disagreement between general practitioners and the two chest specialists was consistent (38%) indicating systematic differences in interpretation. This study raises concerns about differences in the interpretation of spirometry and peak expiratory flow rates in general and hospital practice and the guidelines on which these interpretations are based.
- 1 November 2005
- Published by S. Karger AG in Digestion
- Vol. 72 (4) , 212-218
Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners
Background/Aim: Proton pump inhibitor (PPI) prescribing is costly. The volume of PPI prescription is also increasing, despite little evidence that would justify the increase. General practitioners (GPs) are largely responsible for PPI prescribing, yet knowledge of their views concerning PPIs which might explain the apparent anomaly of prescribing costly drugs without justification is lacking. The aim of this study is therefore to investigate how GPs make decisions about PPI prescribing. Method: Qualitative study design using focus groups of 34 GPs and 15 training GPs analysed according to grounded theory principles and use of constant comparative analysis. Results:The participants showed agreement about the clinical factors potentially relevant to PPI prescribing such as age of presentation and endoscopy, issues of Helicobacter pylori eradication and issues around malignancy. There was considerable controversy, however, as to how to apply those factors in real clinical consultations. GPs in training and academic GPs tended to be more conservative; service-based GPs more pragmatic. There was agreement about the need to review long-term PPI medication, but controversy about whether the conventional ‘step-up step-down’ approach was realistic in practice. Good agreement was apparent about the effectiveness, the cost implications, and some of the ethical issues surrounding PPIs, but considerable controversy as to how far such factors should influence prescribing of PPIs. Conclusion:The GPs showed good understanding and knowledge of the issues surrounding PPI prescribing. There was considerable controversy as to how such knowledge should be translated into practice.
- 1 November 2005
- Published by S. Karger AG in Digestion
- Vol. 72 (4) , 212-218
Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners
Background/Aim: Proton pump inhibitor (PPI) prescribing is costly. The volume of PPI prescription is also increasing, despite little evidence that would justify the increase. General practitioners (GPs) are largely responsible for PPI prescribing, yet knowledge of their views concerning PPIs which might explain the apparent anomaly of prescribing costly drugs without justification is lacking. The aim of this study is therefore to investigate how GPs make decisions about PPI prescribing. Method: Qualitative study design using focus groups of 34 GPs and 15 training GPs analysed according to grounded theory principles and use of constant comparative analysis. Results:The participants showed agreement about the clinical factors potentially relevant to PPI prescribing such as age of presentation and endoscopy, issues of Helicobacter pylori eradication and issues around malignancy. There was considerable controversy, however, as to how to apply those factors in real clinical consultations. GPs in training and academic GPs tended to be more conservative; service-based GPs more pragmatic. There was agreement about the need to review long-term PPI medication, but controversy about whether the conventional ‘step-up step-down’ approach was realistic in practice. Good agreement was apparent about the effectiveness, the cost implications, and some of the ethical issues surrounding PPIs, but considerable controversy as to how far such factors should influence prescribing of PPIs. Conclusion:The GPs showed good understanding and knowledge of the issues surrounding PPI prescribing. There was considerable controversy as to how such knowledge should be translated into practice.
- 24 July 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (s1) , 55-63
Review article: the long‐term use of proton‐pump inhibitors
Summary: More than 15 years after the launch of omeprazole in 1988, proton‐pump inhibitors remain central to the management of acid‐suppression disorders and are unchallenged with regard to their efficacy and popularity among doctors and patients. They are considered safe despite early concerns about the possibility of an association with cancer and gastric atrophy; current concerns about long‐term proton‐pump inhibitor therapy are centred mainly on a possible association with fundic gland polyps and between Helicobacter pylori and gastric atrophic changes. Long‐term proton‐pump inhibitor usage accounts for the majority of the total proton‐pump inhibitor usage. Long‐term usage is difficult to define and most patients take proton‐pump inhibitors non‐continuously. Data indicate that a substantial proportion of long‐term users do not have a clear indication for their therapy and there is thus room for reduction or rationalization of treatment. Overall, on‐demand therapy is more cost‐effective than continuous therapy and should be considered wherever possible.
- 24 July 2005
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (s1) , 55-63
Review article: the long‐term use of proton‐pump inhibitors
Summary: More than 15 years after the launch of omeprazole in 1988, proton‐pump inhibitors remain central to the management of acid‐suppression disorders and are unchallenged with regard to their efficacy and popularity among doctors and patients. They are considered safe despite early concerns about the possibility of an association with cancer and gastric atrophy; current concerns about long‐term proton‐pump inhibitor therapy are centred mainly on a possible association with fundic gland polyps and between Helicobacter pylori and gastric atrophic changes. Long‐term proton‐pump inhibitor usage accounts for the majority of the total proton‐pump inhibitor usage. Long‐term usage is difficult to define and most patients take proton‐pump inhibitors non‐continuously. Data indicate that a substantial proportion of long‐term users do not have a clear indication for their therapy and there is thus room for reduction or rationalization of treatment. Overall, on‐demand therapy is more cost‐effective than continuous therapy and should be considered wherever possible.
- Open Access
- 16 September 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (7) , 733-744
The effect of Helicobacter pylori and its eradication on gastro‐oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis
Summary: Background : The effect of Helicobacter pylori in provoking or protecting against gastro‐oesophageal reflux disease is unclear and studies have given conflicting results. Recent guidelines recommend H. pylori eradication in patients on long‐term proton pump inhibitors.Aim : To ascertain the effect of H. pylori eradication on gastro‐oesophageal reflux disease outcomes (reflux oesophagitis and heartburn) in patients with duodenal ulcer disease, and to ascertain the effect of H. pylori infection on reflux oesophagitis concerning heartburn, pH, severity, healing and relapse rates.Methods : A systematic review of electronic databases was undertaken to September 2003. Experts in the field, pharmaceutical companies and journals were contacted about unpublished trials. Studies were reviewed according to predefined eligibility and quality criteria. Twenty‐seven studies/trials were included in the systematic review.Results : Study variation rather than therapy‐influenced results in relation to the presence or absence of oesophagitis in patients with duodenal ulcer who underwent H. pylori eradication at 6–48 months follow‐up. In patients with reflux oesophagitis no obvious differences were discovered in heartburn scores, 24‐h pH values, healing and relapse rates between H. pylori‐positive and ‐negative cases.Conclusion : There is no evidence to indicate that H. pylori eradication in duodenal ulcer disease provokes reflux oesophagitis or worsens heartburn; (ii) there are insufficient data to draw firm conclusions about the impact of H. pylori in patients with reflux oesophagitis.
- 16 September 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (7) , 733-744
Open AccessThe effect of Helicobacter pylori and its eradication on gastro‐oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis
Summary: Background : The effect of Helicobacter pylori in provoking or protecting against gastro‐oesophageal reflux disease is unclear and studies have given conflicting results. Recent guidelines recommend H. pylori eradication in patients on long‐term proton pump inhibitors.Aim : To ascertain the effect of H. pylori eradication on gastro‐oesophageal reflux disease outcomes (reflux oesophagitis and heartburn) in patients with duodenal ulcer disease, and to ascertain the effect of H. pylori infection on reflux oesophagitis concerning heartburn, pH, severity, healing and relapse rates.Methods : A systematic review of electronic databases was undertaken to September 2003. Experts in the field, pharmaceutical companies and journals were contacted about unpublished trials. Studies were reviewed according to predefined eligibility and quality criteria. Twenty‐seven studies/trials were included in the systematic review.Results : Study variation rather than therapy‐influenced results in relation to the presence or absence of oesophagitis in patients with duodenal ulcer who underwent H. pylori eradication at 6–48 months follow‐up. In patients with reflux oesophagitis no obvious differences were discovered in heartburn scores, 24‐h pH values, healing and relapse rates between H. pylori‐positive and ‐negative cases.Conclusion : There is no evidence to indicate that H. pylori eradication in duodenal ulcer disease provokes reflux oesophagitis or worsens heartburn; (ii) there are insufficient data to draw firm conclusions about the impact of H. pylori in patients with reflux oesophagitis.
- 1 July 2004
- Published by SAGE Publications in Primary Health Care Research & Development
- Vol. 5 (3) , 264-273
The case for multidisciplinary research in primary care
- 1 July 2004
- Published by SAGE Publications in Primary Health Care Research & Development
- Vol. 5 (3) , 264-273
The case for multidisciplinary research in primary care
Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review
Objectives: To ascertain the prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease and its association with the disease. Design: Systematic review of studies reporting the prevalence of H pylori in patients with and without gastro-oesophageal reflux disease. Data sources: Four electronic databases, searched to November 2001, experts, pharmaceutical companies, and journals. Main outcome measure: Odds ratio for prevalence of H pylori in patients with gastro-oesophageal reflux disease. Results: 20 studies were included. The pooled estimate of the odds ratio for prevalence of H pylori was 0.60 (95% confidence interval 0.47 to 0.78), indicating a lower prevalence in patients with gastro-oesophageal reflux disease. Substantial heterogeneity was observed between studies. Location seemed to be an important factor, with a much lower prevalence of H pylori in patients with gastro-oesophageal reflux disease in studies from the Far East, despite a higher overall prevalence of infection than western Europe and North America. Year of study was not a source of heterogeneity. Conclusion: The prevalence of H pylori infection was significantly lower in patients with than without gastro-oesophageal reflux, with geographical location being a strong contributor to the heterogeneity between studies. Patients from the Far East with reflux disease had a lower prevalence of H pylori infection than patients from western Europe and North America, despite a higher prevalence in the general population. What is already known on this topic: The relation between H pylori infection and gastro-oesophageal reflux disease is controversial Studies on the prevalence of H pylori in patients with gastro-oesophageal reflux disease have given conflicting results Recent guidelines recommend eradication of H pylori in patients requiring long term proton pump inhibitors, essentially for reflux disease What this study adds: Despite heterogeneity between studies, the prevalence of H pylori was significantly lower in patients with than without gastro-oesophageal reflux disease Further well designed studies are required to establish the clinical relevance of the findings, particularly in eradication therapy
Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review
Objectives: To ascertain the prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease and its association with the disease. Design: Systematic review of studies reporting the prevalence of H pylori in patients with and without gastro-oesophageal reflux disease. Data sources: Four electronic databases, searched to November 2001, experts, pharmaceutical companies, and journals. Main outcome measure: Odds ratio for prevalence of H pylori in patients with gastro-oesophageal reflux disease. Results: 20 studies were included. The pooled estimate of the odds ratio for prevalence of H pylori was 0.60 (95% confidence interval 0.47 to 0.78), indicating a lower prevalence in patients with gastro-oesophageal reflux disease. Substantial heterogeneity was observed between studies. Location seemed to be an important factor, with a much lower prevalence of H pylori in patients with gastro-oesophageal reflux disease in studies from the Far East, despite a higher overall prevalence of infection than western Europe and North America. Year of study was not a source of heterogeneity. Conclusion: The prevalence of H pylori infection was significantly lower in patients with than without gastro-oesophageal reflux, with geographical location being a strong contributor to the heterogeneity between studies. Patients from the Far East with reflux disease had a lower prevalence of H pylori infection than patients from western Europe and North America, despite a higher prevalence in the general population. What is already known on this topic: The relation between H pylori infection and gastro-oesophageal reflux disease is controversial Studies on the prevalence of H pylori in patients with gastro-oesophageal reflux disease have given conflicting results Recent guidelines recommend eradication of H pylori in patients requiring long term proton pump inhibitors, essentially for reflux disease What this study adds: Despite heterogeneity between studies, the prevalence of H pylori was significantly lower in patients with than without gastro-oesophageal reflux disease Further well designed studies are required to establish the clinical relevance of the findings, particularly in eradication therapy